Table 1.
Baseline patient characteristics.
| NUMBER OF PATIENTS | n (%) 29 (100) |
|---|---|
| Characteristic at diagnosis | |
| Primary site of disease | |
| Colon | 16 (55) |
| Rectum | 13 (45) |
| Disease status | |
| Synchronous | 15 (51) |
| Metachronous | 14 (49) |
| KRAS mutation | |
| Yes | 15 (51) |
| No | 14 (49) |
| Characteristic at baseline regorafenib | |
| Age, year, median (range) | 68 (40–83) |
| ECOG performance status, | n (%) |
| 0 | 7 (24) |
| 1 | 18 (62) |
| 2 | 4 (14) |
| Site of metastasis | |
| Liver | 21 (72) |
| Lung | 19(65) |
| Lymph Nodes | 8 (27) |
| Peritoneal | 6 (21) |
| Other | 8 (27) |
| No of previous palliative systemic anticancer therapies | |
| <3 | 6 (21) |
| 3 | 12 (41) |
| 4 | 8 (28) |
| 5 | 3 (10) |
| Previous Bevacizumab treatment | |
| Yes | 26 (90) |
| No | 3 (10) |
| Previous anti-EGFR treatment | |
| Yes | 14 (51) |
| No | 15 (49) |
Abbreviations: No, number; ECOG, Eastern Cooperative Oncology Group; EGFR, epithelial growth factor receptor.